In the late 1990s, Tim Keith was the leader of a team at a company called Genome Therapeutics that discovered ADAM33, the first gene to be associated with asthma. The milestone paper, published in Nature in 2002, "is probably one of the most widely cited papers in the asthma field," says Stephen Holgate of the University of Southampton, who supplied DNA samples collected from families in the United Kingdom. Although no drugs have yet emerged from the pipeline, Schering Plough (Genome Therapeutics' corporate partner in the ADAM33 discovery) has been working on turning the findings into novel therapies for the treatment and prevention of the disease.
Survey Series
For Advertisers
From Buckets of Banana Mash
Genizon CSO Tim Keith's cautious but rigorous approach has made it possible for companies to separate real data from noise.
(continued >>)
To continue reading this full article, you must be a subscriber to The Scientist.
You are only a few minutes away from unlimited access.
If you already have an online subscription, please Log-In Now.
New to The Scientist? Register to get access to a selection of our content, interactive features and useful tools free without a subscription.
New to The Scientist? Register to get access to a selection of our content, interactive features and useful tools free without a subscription.
Subscribe to The Scientist to get unlimited access to our premium content
Get unlimited access to this article and over 20 years of The Scientist archives. You won’t miss a word – all for as little as $4.95. Subscribe now.The Scientist offers site licenses to institutions and organizations. Recommend us to your librarian and get online access through your place or work or study.